Ryvu Therapeutics (WAR:RVU) Valuation Rank

View and export this data going back to 2011. Start your Free Trial

What is Ryvu Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Ryvu Therapeutics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Ryvu Therapeutics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Ryvu Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ryvu Therapeutics SA (WAR:RVU) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

9Y4:Germany

Address

Leona Henryka Sternbacha 2, Krakow, POL, 30-394

Website

https://www.ryvu.com

Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.